ReviewFrontiers in psychiatry2016
The Genetic Basis of Cognitive Impairment and Dementia in Parkinson's Disease.
Review in Frontiers in psychiatry, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 1 synthesis or guideline pooled it, 61 citations in OpenAlex.
- The genetic association between apolipoprotein E gene polymorphism and Parkinson disease: A meta-Analysis of 47 studies.Medicine · 2018Pooled it
- Neuropathology in genetic Parkinson's disease: a focused review of pathological and clinical findings.Journal of neural transmission (Vienna, Austria : 1996) · 2026Review
- The effect of Apolipoprotein E4 on cognitive function in Parkinson's disease: A structural MRI study in the PPMI cohort.PloS one · 2026Article
- Toward common treatment strategies: convergent proteinopathies and mitochondrial dysfunction in Alzheimer's and Parkinson's diseases.Frontiers in neuroscience · 2026Review
- Alpha-Synuclein Neurobiology in Parkinson's Disease: A Comprehensive Review of Its Role, Mechanisms, and Therapeutic Perspectives.Brain sciences · 2025Review
- Effective Functional Pattern Between Prefrontal fNIRS Activity and Cognitive Performance in Patients With Parkinson's Disease: A Data-Driven PLS Approach.Brain and behavior · 2025Article
- Predicting cognition after subthalamic Deep Brain Stimulation in Parkinson's Disease.NPJ Parkinson's disease · 2025Article
- The role ofFrontiers in neuroscience · 2025Review
- GWAS Identifies DPP6 as Risk Gene of Cognitive Decline in Parkinson's Disease.The journals of gerontology. Series A, Biological sciences and medical sciences · 2024Article
- Neuroinflammation is linked to dementia risk in Parkinson's disease.Brain : a journal of neurology · 2024Article
- Risk Factors for Postoperative Delirium Severity After Deep Brain Stimulation Surgery in Parkinson's Disease.Journal of Parkinson's disease · 2024Article
- The Mechanisms of the Roles of α-Synuclein, Amyloid-β, and Tau Protein in the Lewy Body Diseases: Pathogenesis, Early Detection, and Therapeutics.International journal of molecular sciences · 2023Review
- Heritability of cognitive abilities and regional brain structures in middle-aged to elderly East Asians.Cerebral cortex (New York, N.Y. : 1991) · 2023Article
- Mutant glucocerebrosidase impairs α-synuclein degradation by blockade of chaperone-mediated autophagy.Science advances · 2022Article
- Genetics in parkinson's disease: From better disease understanding to machine learning based precision medicine.Frontiers in molecular medicine · 2022Review
- TOMM40 '523' poly-T repeat length is a determinant of longitudinal cognitive decline in Parkinson's disease.NPJ Parkinson's disease · 2021Article
- Cognitive Impairment in Parkinson's Disease: Epidemiology, Clinical Profile, Protective and Risk Factors.Behavioral sciences (Basel, Switzerland) · 2021Review
- An update on blood-based biomarkers for non-Alzheimer neurodegenerative disorders.Nature reviews. Neurology · 2020Review
- Disease modification and biomarker development in Parkinson disease: Revision or reconstruction?Neurology · 2020Review
- Mini Review: Correlations of Cognitive Domains With Cerebrospinal Fluid α-Synuclein Levels in Patients With Parkinson's Disease.Frontiers in aging neuroscience · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cognitive dysfunction is a common feature of Parkinson's disease (PD) with mild cognitive impairment affecting around a quarter of patients in the early stages of their disease, and approximately half developing dementia by 10 years from diagnosis. However, the pattern of cognitive impairments and their speed of evolution vary markedly between individuals. While some of this variability may relate to extrinsic factors and comorbidities, inherited genetic heterogeneity is also known to play an important role. A number of common genetic variants have been identified, which contribute to cognitive function in PD, including variants in catechol-O-methyltransferase, microtubule-associated protein tau, and apolipoprotein E. Furthermore, rarer mutations in glucocerebrosidase and α-synuclein and are strongly associated with dementia risk in PD. This review explores the functional impact of these variants on cognition in PD and discusses how such genotype-phenotype associations provide a window into the mechanistic basis of cognitive heterogeneity in this disorder. This has consequent implications for the development of much more targeted therapeutic strategies for cognitive symptoms in PD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.